PCVX EBITDA | VAXCYTE, INC.

VAXCYTE, INC. (PCVX) EBITDA

2026-06-30: Basis Reported; EBITDA -$299.77M*; Operating income -$302.78M; Depreciation and amortization $3.00M*.
2026-03-31: Basis Reported; EBITDA -$342.9M; Operating income (m); Depreciation and amortization (m).
2025-12-31: Basis Reported; EBITDA -$266.79M; Operating income (m); Depreciation and amortization (m).
2025-09-30: Basis Reported; EBITDA -$239.32M*; Operating income -$242.38M; Depreciation and amortization $3.06M*.

Complete source-backed ebitda history.

Available history: 2018-12-31 to 2026-03-31
Data captured: 2026-09-04

Historical EBITDA

EBITDA 3 month

Date	Basis	EBITDA	Operating income	Depreciation and amortization	Revenue	EBITDA margin	Capital spending	Operating cash flow	Cost of products and services	Research and development	Selling, general and administration	Income tax expense / benefit
2026-06-30	Reported	-$299.77M*	-$302.78M	$3.00M*	(m)	(m)	$4.32M*	-$232.47M*	(m)	$267.85M	(m)	$0.00
2026-03-31	Reported	-$342.9M	(m)	(m)	(m)	(m)	$2.11M	-$280.63M	(m)	$312.78M	(m)	$0.00
2025-12-31	Reported	-$266.79M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2025-09-30	Reported	-$239.32M*	-$242.38M	$3.06M*	(m)	(m)	$3.82M*	-$143.31M*	(m)	$209.93M	(m)	$0.00
2025-06-30	Reported	-$223.34M*	-$226.22M	$2.88M*	(m)	(m)	$1.81M*	-$121.17M*	(m)	$194.18M	(m)	$0.00
2025-03-31	Reported	-$177.84M	(m)	(m)	(m)	(m)	$5.42M	-$166.27M	(m)	$148.13M	(m)	$0.00
2024-12-31	Reported	-$159.31M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2024-09-30	Reported	-$138.14M*	-$139.92M	$1.79M*	(m)	(m)	$4.95M*	-$60.71M*	(m)	$116.94M	(m)	$0.00
2024-06-30	Reported	-$151.63M*	-$152.98M	$1.35M*	(m)	(m)	$7.78M*	-$121.39M*	(m)	$131.51M	(m)	$0.00
2024-03-31	Reported	-$113.47M	(m)	(m)	(m)	(m)	$5.68M	-$159.12M	(m)	$94.59M	(m)	$0.00
2023-12-31	Reported	-$195.79M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2023-09-30	Reported	-$112.22M*	-$113.03M	$806.00K*	(m)	(m)	$7.34M*	-$57.55M*	(m)	$97.42M	(m)	$0.00
2023-06-30	Reported	-$86.40M*	-$87.15M	$750.00K*	(m)	(m)	-$2.14M*	-$62.74M*	(m)	$72.69M	(m)	$0.00
2023-03-31	Reported	-$70.48M	(m)	(m)	(m)	(m)	$5.61M	-$47.69M	(m)	$58.08M	(m)	$0.00
2022-12-31	Reported	-$85.61M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2022-09-30	Reported	-$57.89M*	-$58.58M	$684.00K*	(m)	(m)	$843.00K*	-$38.55M*	(m)	$47.68M	(m)	$0.00
2022-06-30	Reported	-$47.28M*	-$47.89M	$609.00K*	(m)	(m)	$938.00K*	-$39.13M*	(m)	$38.47M	(m)	$0.00
2022-03-31	Reported	-$38.64M	(m)	(m)	(m)	(m)	$2.92M	-$27.70M	(m)	$31.68M	(m)	$0.00
2021-12-31	Reported	-$29.39M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2021-09-30	Reported	-$26.44M*	-$26.95M	$510.00K*	(m)	(m)	$1.72M*	-$28.41M*	(m)	$20.43M	(m)	$0.00
2021-06-30	Reported	-$23.25M*	-$23.73M	$484.00K*	(m)	(m)	$2.21M*	-$28.68M*	(m)	$17.65M	(m)	$0.00
2021-03-31	Reported	-$22.8M	(m)	(m)	(m)	(m)	$1.25M	-$13.21M	(m)	$17.26M	(m)	$0.00
2020-12-31	Reported	-$19.12M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	$14.66M	(m)	(m)
2020-09-30	Reported	-$20.97M*	-$21.31M	$334.00K*	(m)	(m)	$29.00K*	-$13.05M*	(m)	$16.41M	(m)	$0.00
2020-06-30	Reported	-$20.87M*	-$21.22M	$355.00K*	(m)	(m)	$55.00K*	-$9.17M*	(m)	$18.18M	(m)	$0.00
2020-03-31	Reported	-$27.21M	(m)	(m)	(m)	(m)	$349.00K	-$13.63M	(m)	$24.32M	(m)	(m)
2019-12-31	Reported	-$15.51M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	$13.38M	(m)	(m)
2019-09-30	Reported	-$11.84M*	-$12.14M	$304.00K*	(m)	(m)	$60.00K*	-$9.46M*	(m)	$9.63M	(m)	(m)
2019-06-30	Reported	(m)	-$12.23M	(m)	(m)	(m)	(m)	(m)	(m)	$9.97M	(m)	(m)
2019-03-31	Reported	(m)	-$13.94M	(m)	(m)	(m)	(m)	(m)	(m)	$12.63M	(m)	(m)

EBITDA 12 month

Date	Basis	EBITDA	Operating income	Depreciation and amortization	Revenue	EBITDA margin	Capital spending	Operating cash flow	Cost of products and services	Research and development	Selling, general and administration	Income tax expense / benefit
2025-12-31	Reported	-$907.28M	(m)	(m)	(m)	(m)	$13.71M	-$655.58M	(m)	$794.31M	(m)	$0.00
2024-12-31	Reported	-$562.54M	(m)	(m)	(m)	(m)	$22.43M	-$452.63M	(m)	$476.64M	(m)	$0.00
2023-12-31	Reported	-$464.89M	(m)	(m)	(m)	(m)	$16.06M	-$296.79M	(m)	$332.34M	(m)	$0.00
2022-12-31	Reported	-$229.42M	(m)	(m)	(m)	(m)	$5.84M	-$170.60M	(m)	$169.45M	(m)	(m)
2021-12-31	Reported	-$101.87M	(m)	(m)	(m)	(m)	$6.55M	-$121.39M	(m)	$78.41M	(m)	(m)
2021-09-30	Rolling	(m)	-$93.28M*	(m)	(m)	(m)	(m)	(m)	(m)	$70.00M*	(m)	(m)
2021-06-30	Rolling	(m)	-$87.63M*	(m)	(m)	(m)	(m)	(m)	(m)	$65.98M*	(m)	(m)
2021-03-31	Rolling	(m)	-$85.13M*	(m)	(m)	(m)	(m)	(m)	(m)	$66.51M*	(m)	(m)
2020-12-31	Reported	-$88.18M	(m)	(m)	(m)	(m)	$1.16M	-$46.63M	(m)	$73.56M	(m)	(m)
2020-12-31	Rolling	(m)	-$89.58M*	(m)	(m)	(m)	(m)	(m)	(m)	$73.56M*	(m)	(m)
2020-09-30	Rolling	(m)	-$85.97M*	(m)	(m)	(m)	(m)	(m)	(m)	$72.28M*	(m)	(m)
2020-06-30	Rolling	(m)	-$76.80M*	(m)	(m)	(m)	(m)	(m)	(m)	$65.50M*	(m)	(m)
2020-03-31	Rolling	(m)	-$67.81M*	(m)	(m)	(m)	(m)	(m)	(m)	$57.29M*	(m)	(m)
2019-12-31	Reported	-$52.92M	(m)	(m)	(m)	(m)	$1.20M	-$47.15M	(m)	$45.61M	(m)	(m)
2019-12-31	Rolling	(m)	-$54.15M*	(m)	(m)	(m)	(m)	(m)	(m)	$45.61M*	(m)	(m)
2018-12-31	Reported	-$34.5M	(m)	(m)	(m)	(m)	$1.77M	-$30.47M	(m)	$30.14M	(m)	(m)

Similar stocks

Stock Name	Country	Market Cap	PE Ratio
ImmunityBio, Inc. (IBRX)	United States	$9.157B	-9.29
Kymera Therapeutics, Inc. (KYMR)	United States	$9.631B	-31.69
Immunovant, Inc. (IMVT)	United States	$7.028B	-14.78
Krystal Biotech, Inc. (KRYS)	United States	$10.210B	45.56
REPLIGEN CORP (RGEN)	United States	$10.755B	185.31
CG Oncology, Inc. (CGON)	United States	$6.095B	-27.95
Scholar Rock Holding Corp (SRRK)	United States	$5.920B	-16.37
BIO-TECHNE Corp (TECH)	United States	$11.379B	74.68
Twist Bioscience Corp (TWST)	United States	$11.540B	-47.21
CRISPR Therapeutics AG (CRSP)		$5.390B	-11.68